by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : November 2006
Power Driving Down Lipid Targets1,2 atorvastatin calcium LIPITOR is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. Also indicated in hypertensive patients with multiple risk factors for CHD to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. Refer to Product Information before prescribing. The full disclosure Product Information is available on request from Pfizer Australia Pty Ltd. LIPITOR (atorvastatin calcium). Supplier: Pfizer Australia Pty Ltd, ABN 50 008 422 348, 38–42 Wharf Road, West Ryde NSW 2114. Pfizer Medical Affairs 1800 675 229. Dosage and administration: 10–80mg/day as a single daily dose. LIPITOR can be taken at any time of the day, with or without food. Contraindications: Hypersensitivity to any component of this medication; active liver disease or unexplained persistent elevations of serum transaminases; pregnancy and lactation. Women of child-bearing potential, unless on an effective contraceptive and highly unlikely to conceive. Precautions: Patients who consume substantial quantities of alcohol and/or have a history of liver disease; Myopathy (monitor CK); Risk factors predisposing to development of renal failure secondary to rhabdomyolysis; Use of concomitant medication that may reduce activity/ levels of steroid hormones (ketoconazole, spironolactone and cimetidine); Interactions with other medicines: inhibitors of cytochrome P450 3A4, other HMG-CoA reductase inhibitors, antacid, colestipol, erythromycin/ clarithromycin, protease inhibitors, digoxin, oral contraceptives. Adverse reactions: Headache, asthenia, abdominal pain, dyspepsia, nausea, flatulence, constipation, diarrhoea, insomnia, myalgia. Full disclosure Product Information approved by the TGA on 27 January 2005. Date of most recent amendment: 13 July 2006. PBS dispensed price, August 2006: 10mg $41.19; 20mg $58.32; 40mg $80.03; 80mg $112.19. References: 1. Cannon CP et al. N Engl J Med 2004; 350: 1495-504. 2. LaRosa JC et al. N Engl J Med 2005; 352: 1425-35 LIPITOR *Reg Trademark Pfizer Inc. www.pfizer.com.au 10/06 PFXLI6767B PBS Information: Restricted benefit. For use in patients that meet the criteria set out in the General Statement for Lipid-Lowering Drugs.